Sleep apnea in fragile X premutation carriers with and without FXTAS
- 19 September 2011
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 156 (8) , 923-928
Abstract
This report seeks to establish the prevalence of sleep apnea in patients with the fragile X mental retardation 1 (FMR1) premutation with and without fragile X‐associated tremor/ataxia syndrome (FXTAS) and to determine any correlation between CGG repeat and FMR1 mRNA levels with sleep apnea prevalence. Demographic and medical data from 430 (229 males, 201 females) participants were used in this analysis. Participants included premutation carriers with (n = 118) and without FXTAS (n = 174) as well as controls without the premutation (n = 123). Logistic regression models were employed to estimate the odds ratio of sleep apnea relative to controls, adjusted for age and gender, and also to examine potential association with CGG size and FMR1 mRNA expression level. The observed proportion of sleep apnea in premutation carriers with and without FXTAS and controls are 31.4% (37/118), 8.6% (15/174), and 13.8% (17/123), respectively. The adjusted odds of sleep apnea for premutation carriers with FXTAS is about 3.4 times that compared to controls (odds ratio, OR = 3.4, 95% confidence interval (CI) 1.8–7.4; P = 0.001), and similarly relative to premutation carriers without FXTAS (OR = 2.9, 95% CI 1.2–6.9; P = 0.014). The risk of sleep apnea was not different between controls and premutation carriers without FXTAS. The presence of sleep apnea is not associated with CGG repeat numbers nor FMR1 mRNA expression level among premutation carriers. Our data supports a higher prevalence and risk of sleep apnea in patients with FXTAS. We recommend that all patients diagnosed with FXTAS be screened for sleep apnea given the negative and perhaps accelerative impact sleep apnea may have on their FXTAS progression.Keywords
This publication has 41 references indexed in Scilit:
- Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxinsNeuroToxicology, 2010
- Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndromeBiochemical Journal, 2010
- Advances in understanding the molecular basis of FXTASHuman Molecular Genetics, 2010
- Pathophysiology of Sleep ApneaPhysiological Reviews, 2010
- Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degenerationHuman Molecular Genetics, 2009
- Diagnosis of Obstructive Sleep Apnea in AdultsProceedings of the American Thoracic Society, 2008
- Neuropathic features in fragile X premutation carriersAmerican Journal of Medical Genetics Part A, 2006
- Progression of tremor and ataxia in male carriers of the FMR1 premutationMovement Disorders, 2006
- An Enhanced Polymerase Chain Reaction Assay to Detect Pre- and Full Mutation Alleles of the Fragile X Mental Retardation 1 GeneThe Journal of Molecular Diagnostics, 2005
- Elevated Levels of FMR1 mRNA in Carrier Males: A New Mechanism of Involvement in the Fragile-X SyndromeThe American Journal of Human Genetics, 2000